<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581708</url>
  </required_header>
  <id_info>
    <org_study_id>No.GDREC 2018009H</org_study_id>
    <nct_id>NCT03581708</nct_id>
  </id_info>
  <brief_title>Venous Thromboembolism in Advanced Lung Cancer</brief_title>
  <acronym>RIVAL</acronym>
  <official_title>Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism (VTE) in Chinese Advanced Stage Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observatory clinical study, aiming to establish and validate venous
      thromboembolism risk model in Chinese advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VTE has high incidence in lung cancer and increases the mortality. Appropriate preventive
      measures contribute to 50% increase of incidence. The investigators are to investigate the
      VTE in advanced non-small cell lung cancer and delineate the risk factors to establish a VTE
      risk model system helping clinicians to differentiate VTE high risk population and apply
      early prevention in order to reduce the incidence of VTE.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VTE incidence risk evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Real world VTE incidence risk evaluation in advanced lung cancer. Establish and validate VTE risk predictive model in Chinese advanced lung cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VTE incidence</measure>
    <time_frame>12 months</time_frame>
    <description>VTE incidence in advanced lung cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VTE and overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>The influence on overall survival by VTE.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>advanced lung cancer</arm_group_label>
    <description>Patients diagnosed with advanced lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lung cancer</intervention_name>
    <description>If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence</description>
    <arm_group_label>advanced lung cancer</arm_group_label>
    <other_name>advance lung cancer</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 ml of peripheral blood is drawn from each subject and mononuclear cells are separated for
      DNA extraction, and mutation of Factor V Leiden will be examined.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with advanced staged lung cancer with written informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years at the time of screening.

          -  Eastern Cooperative Oncology Group performance status of ≤ 2.

          -  Written informed consent obtained from the patient.

          -  Histologically and cytologically documented Stage 3B-4 lung cancer (according to
             Version 8 of the International Association for the Study of Lung Cancer Staging
             system).

          -  Patients with stage 1 to 3, who undergo radical therapy with disease free survival
             (DFS) &gt;12 months.

          -  Willingness and ability to comply with scheduled visits and other study procedures.

        Exclusion Criteria:

          -  History of another primary malignancy except for malignancy treated with curative
             intent with known active disease ≥ 5 years before date of the informed consent.

          -  Without signed informed consent.

          -  Unwillingness or inability to comply with scheduled visits or other study procedures.

          -  Previously diagnosed with VTE before signing informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZHEN WANG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ZHEN WANG, PhD</last_name>
    <phone>862083827812</phone>
    <phone_ext>50811</phone_ext>
    <email>hunterol@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>XIAOLING CHEN</last_name>
    <phone>8620-83827812</phone>
    <phone_ext>50816</phone_ext>
    <email>chenxiaoling303@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guagndong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>ZHEN WANG, PhD</last_name>
      <phone>862083827812</phone>
      <phone_ext>50811</phone_ext>
      <email>hunterol@163.com</email>
    </contact>
    <contact_backup>
      <last_name>XIAOLING CHEN</last_name>
      <phone>862083827812</phone>
      <phone_ext>50812</phone_ext>
      <email>chenxiaoling303@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>ZHEN WANG, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. doi: 10.1182/blood-2007-10-116327. Epub 2008 Jan 23.</citation>
    <PMID>18216292</PMID>
  </reference>
  <results_reference>
    <citation>Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9;293(6):715-22.</citation>
    <PMID>15701913</PMID>
  </results_reference>
  <results_reference>
    <citation>Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med. 2007 Sep;13(5):362-7. Review.</citation>
    <PMID>17940477</PMID>
  </results_reference>
  <results_reference>
    <citation>Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999 Sep;78(5):285-91.</citation>
    <PMID>10499070</PMID>
  </results_reference>
  <results_reference>
    <citation>Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002 Jun;87(6):1076-7.</citation>
    <PMID>12083490</PMID>
  </results_reference>
  <results_reference>
    <citation>Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006 Jan;119(1):60-8.</citation>
    <PMID>16431186</PMID>
  </results_reference>
  <results_reference>
    <citation>Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008 Apr;6(4):601-8. doi: 10.1111/j.1538-7836.2008.02908.x. Epub 2008 Jan 17.</citation>
    <PMID>18208538</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang Z, Yan HH, Yang JJ, Wang BC, Chen HJ, Zhou Q, Xu CR, Jiang BY, Wu YL. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer. 2015 Mar;23(3):635-41. doi: 10.1007/s00520-014-2405-y. Epub 2014 Aug 27.</citation>
    <PMID>25155313</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

